AIM ImmunoTech Reports $3.7 Million Net Loss for Q1 2025, Seeks Additional Funding

AIM ImmunoTech Inc. reported a net loss of approximately $3.7 million for the three months ended March 31, 2025, a significant decrease from the $5.8 million loss recorded in the same period of 2024. This reduction in loss, amounting to about $2.1 million or 36%, was attributed to lower research and development costs, which fell by $871,000, and a decrease in general and administrative expenses by $1.3 million. The company’s revenue from clinical treatment programs in the U.S. was $16,000, down from $40,000 in the prior year, primarily due to fluctuations in patient participation.

The company’s total costs and expenses decreased to $3.6 million from $5.8 million year-over-year. This included production costs of $10,000, up from $8,000, while research and development expenses were $1.1 million compared to $2 million in the previous year. General and administrative expenses also saw a decline, totaling $2.5 million, down from $3.8 million. The company reported a basic and diluted loss per share of $(0.05) for the first quarter of 2025, compared to $(0.12) for the same period in 2024.

AIM ImmunoTech continues to focus on its flagship product, Ampligen, which is under development for various cancers and viral diseases. The company is conducting clinical trials, including a Phase 2 study of Ampligen in combination with AstraZeneca’s Imfinzi for late-stage pancreatic cancer, which has received approval to proceed. Additionally, AIM is exploring Ampligen's potential as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-COVID conditions, with ongoing studies showing promising preliminary results.

As of March 31, 2025, AIM had approximately $2.2 million in cash and cash equivalents, a decrease from the previous quarter. The company has faced challenges regarding its stockholder equity, which was reported at a deficit of $3.9 million, below the NYSE American's minimum requirement of $6 million for continued listing. In response, AIM submitted a plan to regain compliance, which was accepted by the NYSE American. However, trading of the company’s stock was suspended on April 4, 2025, due to the stock price falling below $0.10, and it is currently trading on the Pink Open Market under the symbol "AIMI."

Looking ahead, AIM ImmunoTech is actively seeking additional funding to support its operations and clinical trials. The company has entered into an equity distribution agreement with Maxim Group LLC to sell up to $3 million in common stock and has also established a purchase agreement with Atlas Sciences for up to $15 million in common stock over a 24-month period. AIM's management remains focused on advancing its clinical programs and addressing its financial challenges to ensure the continuation of its operations.